Triple negative breast cancer: new therapeutic approaches and BRCA status
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Triple negative breast cancer: new therapeutic approaches and BRCA
status
Authors
Keywords
-
Journal
APMIS
Volume 126, Issue 5, Pages 371-379
Publisher
Wiley
Online
2018-04-26
DOI
10.1111/apm.12836
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel inBRCA1/2metastatic breast cancer: design and rationale
- (2017) Steven J Isakoff et al. Future Oncology
- OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).
- (2017) Mark E. Robson et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
- (2016) Yvette Drew et al. BRITISH JOURNAL OF CANCER
- Genetics of triple-negative breast cancer: Implications for patient care
- (2016) Anosheh Afghahi et al. CURRENT PROBLEMS IN CANCER
- Association of PALB2 sequence variants with the risk of early-onset breast cancer in patients from Turkey
- (2016) G. Cecener et al. MOLECULAR BIOLOGY REPORTS
- PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
- (2016) Karolina N. Dziadkowiec et al. Przeglad Menopauzalny
- Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
- (2016) Brian D. Lehmann et al. PLoS One
- PARP inhibitors in the management of breast cancer: current data and future prospects
- (2015) Luca Livraghi et al. BMC Medicine
- Triple positive breast cancer: A distinct subtype?
- (2015) Patrizia Vici et al. CANCER TREATMENT REVIEWS
- Phase III randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2- BRCA-associated locally advanced or metastatic breast cancer (BC).
- (2015) Shannon Leigh Huggins-Puhalla et al. JOURNAL OF CLINICAL ONCOLOGY
- Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer
- (2015) Fergus J. Couch et al. JOURNAL OF CLINICAL ONCOLOGY
- Triple-negative breast cancer: new perspectives for targeted therapies
- (2015) Silverio Tomao et al. OncoTargets and Therapy
- Triple-Negative Breast Carcinoma
- (2014) Robert Schmadeka et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Triple Negative Breast Cancer
- (2014) Idil Cetin et al. Asian Pacific Journal of Cancer Prevention
- Subtyping of triple-negative breast cancer: Implications for therapy
- (2014) Vandana G. Abramson et al. CANCER
- BRCA1/2Germline Mutations and Their Clinical Importance in Turkish Breast Cancer Patients
- (2014) Gulsah Cecener et al. CANCER INVESTIGATION
- Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?
- (2014) Amir Sonnenblick et al. CANCER TREATMENT REVIEWS
- Distribution ofBRCA1andBRCA2Mutations in Asian Patients with Breast Cancer
- (2014) Haeyoung Kim et al. Journal of Breast Cancer
- Triple-negative breast cancer: future prospects in diagnosis and management
- (2014) Shereef Elsamany et al. MEDICAL ONCOLOGY
- An update on PARP inhibitors—moving to the adjuvant setting
- (2014) Amir Sonnenblick et al. Nature Reviews Clinical Oncology
- Triple-Negative Breast Cancer and the Need for New Therapeutic Targets
- (2013) Olav Engebraaten et al. AMERICAN JOURNAL OF PATHOLOGY
- Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort
- (2013) Rachel Greenup et al. ANNALS OF SURGICAL ONCOLOGY
- Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth?
- (2013) Roxana Chiorean et al. BREAST
- Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
- (2013) H. Masuda et al. CLINICAL CANCER RESEARCH
- Relapsed Triple-Negative Breast Cancer: Challenges and Treatment Strategies
- (2013) Valentina Guarneri et al. DRUGS
- A Comprehensive Focus on Global Spectrum ofBRCA1andBRCA2Mutations in Breast Cancer
- (2013) Fatemeh Karami et al. Biomed Research International
- The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells
- (2013) Silvana B. De Lorenzo et al. Frontiers in Oncology
- Emerging targeted therapies in triple-negative breast cancer
- (2012) J. Crown et al. ANNALS OF ONCOLOGY
- Targeting triple-negative breast cancer: optimising therapeutic outcomes
- (2012) K. Gelmon et al. ANNALS OF ONCOLOGY
- Updates in the treatment of basal/triple-negative breast cancer
- (2012) Mythili Shastry et al. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
- Targeted therapy for triple-negative breast cancer: Where are we?
- (2012) Michael J. Duffy et al. INTERNATIONAL JOURNAL OF CANCER
- Are We Ready for Online Tools in Decision Making for BRCA1/2 Mutation Carriers?
- (2012) D. Gareth Evans et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations
- (2011) Soley Bayraktar et al. BREAST CANCER RESEARCH AND TREATMENT
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Characteristics of Triple-Negative Breast Cancer in Patients With a BRCA1 Mutation: Results From a Population-Based Study of Young Women
- (2011) Eunjung Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Microarray-Based Class Discovery for Molecular Classification of Breast Cancer: Analysis of Interobserver Agreement
- (2011) Alan Mackay et al. JNCI-Journal of the National Cancer Institute
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- A snapshot of chemoresistance to PARP inhibitors
- (2011) Alberto Chiarugi TRENDS IN PHARMACOLOGICAL SCIENCES
- The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy
- (2011) M. Javle et al. Therapeutic Advances in Medical Oncology
- Germline mutations of BRCA1 and BRCA2 genes in Turkish breast, ovarian, and prostate cancer patients
- (2010) Esra Manguoğlu et al. CANCER GENETICS AND CYTOGENETICS
- Triple-Negative Breast Cancer
- (2010) Steven J. Isakoff CANCER JOURNAL
- Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction
- (2010) A. C. Antoniou et al. CANCER RESEARCH
- Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in Cancer
- (2010) C. M. Annunziata et al. CLINICAL CANCER RESEARCH
- Treatment options for patients with triple-negative breast cancer
- (2010) Rafael Santana-Davila et al. Journal of Hematology & Oncology
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Triple-negative breast cancer: Present challenges and new perspectives
- (2010) Franca Podo et al. Molecular Oncology
- Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
- (2009) B. Corkery et al. ANNALS OF ONCOLOGY
- Triple-negative breast cancer--current status and future directions
- (2009) O. Gluz et al. ANNALS OF ONCOLOGY
- The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers
- (2009) Yvette Drew et al. Annals of the New York Academy of Sciences
- BRCA1andBRCA2mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer
- (2009) Michael J. Hall et al. CANCER
- Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design
- (2009) Farrah Kassam et al. Clinical Breast Cancer
- Pharmacotherapy of triple-negative breast cancer
- (2009) Cagatay Arslan et al. EXPERT OPINION ON PHARMACOTHERAPY
- Triple-negative breast cancer: Novel therapies and new directions
- (2009) Sumanta Kumar Pal et al. MATURITAS
- Drug Resistance Caused by Reversion Mutation
- (2008) A. Ashworth CANCER RESEARCH
- Targeted therapy for cancer using PARP inhibitors
- (2008) Christopher J Lord et al. CURRENT OPINION IN PHARMACOLOGY
- What is triple-negative breast cancer?
- (2008) William J. Irvin et al. EUROPEAN JOURNAL OF CANCER
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search